Fermentation einer Triolheptansäure durch Mutantenstämme von Aspergillus terreus

Novel strains of Aspergillus terreus have been discovered which provide fermentation production of at least 5.2 g/L of 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naph thyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid, I), but with production of not more than 0.85 g/L of (tri...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: VINCI, VICTOR A., CHARLOTTESVILLE, VIRGINIA 22901, US, DABORA, REBECCA L., ANDOVER, MASSACHUSETTS 01810, US, STIEBER, ROBERT W., HARRISONBURG, VIRGINIA 22801, US, HONG, ANDERSON, PEITAU, TAIPEI, TAIWAN 112, CN, COVER, WILLIAM H., LANSDALE, PA 19446, US, REEVES, CHRISTOPHER, MILL CREEK, WASHINGTON 98012, US
Format: Patent
Sprache:ger
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Novel strains of Aspergillus terreus have been discovered which provide fermentation production of at least 5.2 g/L of 7-[1,2,6,7,8,8a(R)-hexahydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naph thyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid, I), but with production of not more than 0.85 g/L of (triol acid)-related side products and specifically less than 0.10 mg/liter of lovastatin. The predominant fermentation product triol acid, may be converted in a straightforward manner to its lactone form, in which it is an inhibitor of HMG-CoA reductase and thus useful as an antihypercholesterolemic agent, and in which it may also serve as an intermediate for preparation of other HMG-CoA reductase inhibitors.